CN Patent

CN113795255A — 使用布鲁顿酪氨酸激酶抑制剂治疗慢性自发性荨麻疹的方法

Assigned to Novartis AG · Expires 2021-12-14 · 4y expired

What this patent protects

本披露涉及使用具有式(I)的化合物或其药学上可接受的盐治疗慢性自发性荨麻疹的方法。本文还披露了用于治疗慢性自发性荨麻疹患者的具有式(I)的化合物或其药学上可接受的盐，以及用于所披露的用途和方法的药物、给药方案、药物配制品、剂型和试剂盒。

USPTO Abstract

本披露涉及使用具有式(I)的化合物或其药学上可接受的盐治疗慢性自发性荨麻疹的方法。本文还披露了用于治疗慢性自发性荨麻疹患者的具有式(I)的化合物或其药学上可接受的盐，以及用于所披露的用途和方法的药物、给药方案、药物配制品、剂型和试剂盒。

Drugs covered by this patent

Patent Metadata

Patent number: CN113795255A
Jurisdiction: CN
Classification: —
Expires: 2021-12-14
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.